Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Experts point to lessons learned from controversy over rofecoxib safety

Article Abstract:

Patients and physicians have raised concern regarding the safety of other drugs that preferentially inhibit the cyclooxygenase-2 COX-2) enzyme which was pulled from the market due to life-threatening adverse cardiovascular events. It is suggested that extensive pharmacoepidemiological studies for drugs, which include examining a drug's effects over a longer period and address a more representative patient population than is seen in randomized trials.

Author: Hampton, Tracy
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
Product quality, Cardiovascular diseases, Complications and side effects, Risk factors, Quality management, Pharmaceutical research, Rofecoxib

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


1918 flu vaccine effective in mice

Article Abstract:

Scientists from the National Institute of Health, the Centers for Disease Control and Prevention and the Mount Sinai School of Medicine found that all mice survived an intranasal challenge of live, reconstructed 1981 virus given 14 days after immunization with DNA vaccine. The vaccine consisted of a vector expressing the virus's gene for hemagglutinin, a protein that allows the flu virus to bind cell and cause infection.

Author: Hampton, Tracy
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2006
Patient outcomes, Influenza vaccines, Influenza, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Cancer agents show first-line potential

Article Abstract:

The trial results for the safety and efficacy of some of agents such as arsenic trioxide for acute promyelocytic leukemia, desatinib for chronic myelogenous leukemia and bevacizumab for renal cell carcinoma as potential new first-line treatments for patients with cancer is discussed.

Author: Hampton, Tracy
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2007
Dosage and administration, Chronic myeloid leukemia, Carcinoma, Renal cell, Renal cell carcinoma, Bevacizumab

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Drug therapy
Similar abstracts:
  • Abstracts: The perceived impact of duty hour restrictions on the residency environment: A survey of residency program directors
  • Abstracts: Evaluating a project to improve care of older people in Scotland. Providing older patients with holistic health promotion
  • Abstracts: Changes in left thoracic duct lymph flow during progressive anemia in the ovine fetus. Regulation of amniotic fluid volume: Intramembranous solute and volume fluxes in late gestation fetal sheep
  • Abstracts: Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. The seroepidemiology of human T-lymphotropic viruses: Types I and II in Europe: A prospective study of pregnant women
  • Abstracts: Medical students protest perks from drug companies. Activists protest national parks proposal to profit from microbes
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.